Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Receivables (2020 - 2023)

Relay Therapeutics (RLAY) has disclosed Receivables for 4 consecutive years, with $211000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Receivables fell 95.88% to $211000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $211000.0, a 95.88% decrease, with the full-year FY2022 number at $5.2 million, up 6.45% from a year prior.
  • Receivables was $211000.0 for Q3 2023 at Relay Therapeutics, up from $78000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $82.7 million in Q4 2020 to a low of $78000.0 in Q2 2023.
  • A 4-year average of $11.2 million and a median of $5.1 million in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: rose 12.97% in 2022, then plummeted 98.46% in 2023.
  • Relay Therapeutics' Receivables stood at $82.7 million in 2020, then plummeted by 94.07% to $4.9 million in 2021, then increased by 6.45% to $5.2 million in 2022, then crashed by 95.96% to $211000.0 in 2023.
  • Per Business Quant, the three most recent readings for RLAY's Receivables are $211000.0 (Q3 2023), $78000.0 (Q2 2023), and $5.2 million (Q1 2023).